Bacteriophage gene 3 protein compositions and use as amyloid binding agents
AssigneeProclara Biosciences, Inc.
InventorsRajaraman Krishnan, Richard Fisher
Life of this patent
Estimating the term…
Abstract
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
Claims15
A pharmaceutical composition comprising a fusion protein that comprises an amyloid-binding polypeptide and an immunoglobulin IgG constant region,
- wherein the amyloid binding polypeptide is present in an amount sufficient to treat a disease or disorder associated with misfolded and/or aggregated amyloid protein and a pharmaceutically acceptable carrier, and
- wherein the polypeptide comprises at least one of:
- (a) a wild type g3p;
- (b) an amyloid-binding fragment of wild type g3p;
- or
- (c) a mutant of (a) or (b) that retains the ability to bind to amyloid.
A pharmaceutical composition comprising a fusion protein that comprises an immunoglobulin IgG constant region and an amyloid-binding polypeptide in an amount sufficient to treat a disease or disorder associated with misfolded and/or aggregated amyloid protein and a pharmaceutically acceptable carrier;
- wherein the polypeptide comprises at least one of:
- (a) a wild type g3p,
- (b) an amyloid-binding fragment of wild type g3p, or
- (c) a mutant of (a) or (b) that retains the ability to bind to amyloid;
- wherein the pharmaceutical composition is in unit dosage form.
A composition comprising a detectable label joined to a fusion protein that is capable of binding to misfolded and/or aggregated amyloid protein, and comprises an immunoglobulin IgG constant region and at least one amyloid-binding polypeptide selected from:
- (a) a wild type g3p that comprises a full-length N2 domain,
- (b) an amyloid-binding fragment of wild type g3p that comprises a full-length N2 domain,
- (c) a mutant g3p that comprises a full-length N2 domain or corresponding mutant thereof that retains the ability to bind to amyloid, or
- (d) a mutant amyloid-binding fragment of g3p that comprises a full-length N2 domain or corresponding mutant thereof that retains the ability to bind to amyloid.
Dependencies are inferred from the claim text.